Therapeutics development in SMA: Difference between revisions
New page: {{CMG}} __NOTOC__ {{Editor Help}} |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Spinal Muscular Atrophy}} | |||
{{CMG}} | {{CMG}} | ||
__NOTOC__ | __NOTOC__ | ||
{{Editor Help}} | {{Editor Help}} | ||
Revision as of 14:05, 24 June 2011
|
Spinal Muscular Atrophy Microchapters |
|
Therapeutics development in SMA Resources |
|---|
|
Ongoing Trials on Therapeutics development in SMA at Clinical Trials.gov |
|
US National Guidelines Clearinghouse on Therapeutics development in SMA |
|
Directions to Hospitals Treating Therapeutics development in SMA |
|
Risk calculators and risk factors for Therapeutics development in SMA |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.